The global ear, nose, and throat (ENT) treatment market is expected to grow at a CAGR of around 5.5% from 2021 to 2028 and expected to reach the market value of around US$ 30.2 Bn by 2028.
Ear Nose Throat (ENT) refers to the human body's ear, nose, and throat, which are all interconnected. Otolaryngologists (also known as ENT surgeons) are doctors who specialize in the diagnosis, evaluation, and treatment of diseases of the head and neck, particularly the ears, nose, and throat.
Rising prevalence of ENT related problems due to deterioration of environmental conditions resulting in development of various allergic reactions
According to a MEDSTAR HEALTH report, more than 50 million people in the United States suffer from allergies each year. Otolaryngologists are healthcare providers who specialize in the diagnosis and treatment of ENT conditions, and ENT allergies are among the most common problems they diagnose and treat. Such factors contribute to the expansion of the global ENT treatment market.
New treatment options for ENT fuel the growth of overall market worldwide
As ENT diseases affect the quality of life in humans, a few cases involving chronic tonsillitis, ear infections, and severe sinusitis-related problems may necessitate surgery. According to a report released by South Florida ENT Associates, P.A., sinusitis affects 37 million people each year, making it one of the most common health problems in the United States. Furthermore, sinusitis affects approximately 14% of the adult population in the United States. The annual direct healthcare expenditure associated with sinusitis is well over US$8 Bn. "Balloon SinuplastyTM devices," an endoscopic, catheter-based system, are used to treat sinusitis. The device is currently used on over 80,000 patients, with over 200 cases performed each day. Such new treatment options have a positive impact on the global ENT treatment market's growth.
Research and development stimulate the growth of global ENT treatment market
Loss of hearing capability is one of the most prominent problems associated with sensory deficits among people, according to a report released by the Massachusetts Eye and Ear, affecting approximately 37 million people in the US. Human and other mammalian inner ear cells lack the ability to divide and regenerate, causing harm to the inner ear, particularly the hair cells, and resulting in permanent hear loss. Previous research found that after damage, inner cells in newborn mice can be induced for hair cell division and regeneration. According to the new study, mature inner ear cells can be induced to divide by using a reprogramming approach involving the activation of two molecular signals. As a result, laboratories are focusing on discovering additional drug-like molecules to achieve cell division and hair regeneration in mature inner ear models and large animal models, such as pigs.
The global ENT treatment market is segmented based on organ type, treatment type, and end-user. Organ type is segmented as ears, nose, and throat. Treatment type is bifurcated into devices and drugs. By end-user, the market is segmented as hospitals, clinics, home care settings, and among others.
Based on organ type, the ear segment is expected to dominate the global ENT treatment market, accounting for a significant share during the forecast period. Hearing loss affects millions of people worldwide, according to the World Health Organization (WHO), and is estimated to be the fourth leading cause of disability. Furthermore, approximately 15% of American adults (37.5 million) aged 18 and up report some difficulty hearing. Such factors support segmental growth, ultimately benefiting the ENT treatment market as a whole over the forecast period.
Drugs dominate the global ENT treatment market in terms of treatment type. According to WHO data, the otolaryngologist is primarily responsible for identifying priority ENT conditions in children under the age of 12. It identifies and prescribes the essential medicines required for treating such conditions based on high-quality treatment guidelines. Because drugs are prescribed at the preliminary stage of ENT treatment, it has gained a significant market share in the past and will continue to dominate the overall market throughout the forecast period.
According to end-user, hospitals have held a dominant market share in the global ENT treatment market in the past and are expected to continue in the future. This is because the privatization of the hospital industry in the United States and the United Kingdom has had a significant impact on hospital market structure. Furthermore, the vast majority of hospitals are part of a private hospital network. These factors are largely responsible for segmental growth, which in turn contributes to the global growth of the ENT treatment market.
North America holds dominating share; Asia Pacific to register fastest growing CAGR for the ENT treatment market
North America has demonstrated its dominance in the ENT treatment market in the past by recording a reasonable revenue share, and this trend is expected to continue throughout the forecast period. The presence of prominent players in North America provinces by launching new products to maintain competitiveness has a positive impact on the growth of the ENT treatment market as a whole during the analysis period. Furthermore, the rising prevalence of ear infection among newborn children in the United States is another factor that is positively impacting the growth of ENT treatment. In the United States, for example, by the age of three, 5 out of every 6 children have an ear infection. For records, in December 2019 approx. 736,900 cochlear implants have been implanted in the world among which roughly 118,100 devices have been implanted in adults and 65,000 in children.
Asia Pacific, on the other hand, is expected to have the fastest growing CAGR for the ENT treatment market in the coming years and will continue to do so throughout the forecast period. The APAC regional market for ENT treatment as a whole is driven by rising incidences of hearing impairment among the geriatric population, as well as the development of rising healthcare infrastructure. Furthermore, high awareness about the availability of ENT treatment options through awareness campaigns and program involving China's national ear care day stimulates the growth of the overall ENT treatment market during the forecast period.
The prominent players of the global ENT treatment market involve Medtronic plc, Cochlear, Olympus Corporation, Smith & Nephew plc, Siemens Healthineers, Starkey Hearing Technologies, Demant A/S, and others
Market By Organ Type
Market By Treatment Type
Market By End-user
Home Care Settings
Market By Geography
• Rest of Europe
• South Korea
• Rest of Asia-Pacific
• Rest of Latin America
Middle East & Africa
• South Africa
• Rest of Middle East & Africa
Ear, nose, and throat (ENT) treatment market is expected to reach a market value of around US$ 30.2 Bn by 2028.
The ear, nose, and throat (ENT) treatment market is expected to grow at a CAGR of around 5.5% from 2021 to 2028.
Based on organ type, ears segment is the leading segment in the overall market.
Research and development for new treatment option is one of the prominent factors that drive the demand for ear, nose, and throat (ENT) treatment market.
Medtronic plc, Cochlear, Olympus Corporation, Smith & Nephew plc, Siemens Healthineers, Starkey Hearing Technologies, Demant A/S, and others.
North America is anticipated to grab the highest market share in the regional market
Asia Pacific is expected to be the fastest growing market in the forthcoming years